Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Injectable Drugs Market 2017-2021

Published by TechNavio (Infiniti Research Ltd.) Product code 534674
Published Content info 84 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Injectable Drugs Market 2017-2021
Published: July 26, 2017 Content info: 84 Pages
Description

About Injectable Drugs

Injectable drugs are directly infused into the body with the help of a syringe and a hollow needle. Various modes of infusion are used for the drug delivery. Among them, subcutaneous (SC), intramuscular (IM), and intravenous (IV) are the three major modes. The market encompasses drugs that are used for the prevention and cure of various diseases, and are mainly of two types, namely, biologics and small molecule drugs.

Technavio's analysts forecast the global injectable drugs market to grow at a CAGR of 8.21% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global injectable drugs market for 2017-2021. To calculate the market size, the report considers the sales of vaccines, branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Injectable Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Sanofi

Other Prominent Vendors

  • Bayer
  • Bristol-Myers Squibb
  • Merck
  • Takeda Pharmaceutical
  • Teva Pharmaceutical

Market driver

  • Escalation in demand for self-injection devices
  • For a full, detailed list, view our report

Market challenge

  • High cost of production
  • For a full, detailed list, view our report

Market trend

  • Increase in industry-academia collaboration
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR13955

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline
  • ROA

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by molecule type

  • Biologics
  • Small molecules

PART 08: Geographical segmentation

  • Injectable drugs market in Americas
  • Injectable drugs market in EMEA
  • Injectable drugs market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

  • Market drivers
  • Market challenges

PART 11: Market trends

  • Rising awareness leading to high demand for injectable drugs
  • Increase in industry-academia collaboration
  • Expected entry of novel vaccines
  • Advent of biosimilars

PART 12: Vendor landscape

  • Competitive landscape

PART 13: Key vendor analysis

  • AbbVie
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Sanofi
  • Other prominent vendors

PART 14: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Market scenario: Global injectable drugs market 2016
  • Exhibit 02: Decisive factors for the choice of ROA
  • Exhibit 03: Major ROA for drugs intake
  • Exhibit 04: Types of injections
  • Exhibit 05: Adverse effects of injectable drugs
  • Exhibit 06: Global injectable drugs market snapshot
  • Exhibit 07: Global injectable drugs market 2016-2021 ($ billions)
  • Exhibit 08: Opportunity analysis in global injectable drugs market
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Pipeline molecules by key vendors (Phase III)
  • Exhibit 11: Key clinical trials of key vendors (Phase III)
  • Exhibit 12: Global injectable drugs market segmentation by molecule type
  • Exhibit 13: Global injectable drugs market segmentation by molecule type 2016 and 2021 (%)
  • Exhibit 14: Global biologics injectable drugs market 2016-2021 ($ billions)
  • Exhibit 15: Top biologic drugs in the injectable drugs market
  • Exhibit 16: Global small molecules injectable drugs market 2016-2021 ($ billions)
  • Exhibit 17: Segmentation of global injectable drugs market based on geography 2016 and 2021 (%)
  • Exhibit 18: Global injectable drugs market by geography 2016-2021 ($ billions)
  • Exhibit 19: Market scenario in Americas
  • Exhibit 20: Injectable drugs market in Americas 2016-2021 ($ billions)
  • Exhibit 21: Market scenario in EMEA
  • Exhibit 22: Injectable drugs market in EMEA 2016-2021 ($ billions)
  • Exhibit 23: Market scenario in APAC
  • Exhibit 24: Injectable drugs market in APAC 2016-2021 ($ billions)
  • Exhibit 25: Major indications finding huge applications of injectable drugs
  • Exhibit 26: Major reasons to use injectable drugs
  • Exhibit 27: New cases of diabetes by 2040
  • Exhibit 28: Major complications involved with the injections
  • Exhibit 29: Major causes of drug shortage
  • Exhibit 30: Competitive structure analysis of global injectable drugs market
  • Exhibit 31: AbbVie: Key highlights
  • Exhibit 32: AbbVie: Strength assessment
  • Exhibit 33: AbbVie: Strategy assessment
  • Exhibit 34: AbbVie: Opportunity assessment
  • Exhibit 35: F. Hoffmann-La Roche: Key highlights
  • Exhibit 36: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 37: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 38: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 39: GlaxoSmithKline: Key highlights
  • Exhibit 40: GlaxoSmithKline: Strength assessment
  • Exhibit 41: GlaxoSmithKline: Strategy assessment
  • Exhibit 42: GlaxoSmithKline: Opportunity assessment
  • Exhibit 43: Sanofi: Key highlights
  • Exhibit 44: Sanofi: Strength assessment
  • Exhibit 45: Sanofi: Strategy assessment
  • Exhibit 46: Sanofi: Opportunity assessment
Back to Top